Advertisement

Search Results

Advertisement



Your search for Matthew Stenger,Matthew Stenger matches 7682 pages

Showing 1 - 50


leukemia

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...

breast cancer

Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes

As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...

colorectal cancer

Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal

In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Study Details In the...

prostate cancer

Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer

In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...

head and neck cancer

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...

gastroesophageal cancer

Addition of Lenvatinib/Pembrolizumab to Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma

In an interim analysis of the phase III LEAP-015 trial reported in the Journal of Clinical Oncology, Shitara et al examined the survival benefit of adding lenvatinib-pembrolizumab to chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma. Study Details In the open-label...

breast cancer

Adding Olanzapine to Triplet Antiemetics Post–Anthracycline/Cyclophosphamide Chemotherapy

In a phase III Japanese trial reported in The Lancet Oncology, Saito et al examined the efficacy of adding 5 mg of olanzapine to triplet antiemetic therapy in controlling chemotherapy-induced nausea and vomiting in the overall phase when given after receipt of anthracycline-cyclophosphamide...

survivorship

Mindfulness and Tai Chi Interventions for Mood Improvement in Cancer Survivors With Distress

In a Canadian study (MATCH) reported in the Journal of Clinical Oncology, Carlson et al investigated the effects of mindfulness and Tai Chi interventions on mood in distressed cancer survivors. Study Details In the multisite study, 587 survivors with reported distress, enrolled between 2017 and...

leukemia

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia

In an update from the UK phase III FLAIR trial reported in The New England Journal of Medicine, Munir et al compared the survival benefit of measurable residual disease (MRD)–guided therapy with ibrutinib/venetoclax vs ibrutinib alone in chronic lymphocytic leukemia. An interim analysis showed...

issues in oncology
survivorship

Contributors to Risk of Subsequent Neoplasms in Long-Term Survivors of Childhood Cancer

In a study reported in The Lancet Oncology, Neupane et al explored the question of whether cancer treatment and genetic predisposition are primary contributors to the risk of subsequent neoplasms (SNs) in long-term survivors of childhood cancers. Study Details The study involved data from the St....

pancreatic cancer

Addition of Tumor Treating Fields to Gemcitabine/Nab-Paclitaxel in Locally Advanced Pancreatic Adenocarcinoma

In a phase III trial (PANOVA-3) reported in the Journal of Clinical Oncology, Babiker et al examined the survival benefit of using tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in patients with unresectable locally advanced pancreatic adenocarcinoma. Study Details In the global...

breast cancer

Regional Nodal Irradiation in Node-Negative Breast Cancer After Neoadjuvant Chemotherapy

In a phase III trial (NSABP B-51–RTOG 1304) reported in The New England Journal of Medicine, Mamounas et al examined regional nodal irradiation for activity in preventing invasive breast cancer recurrence or death from breast cancer in patients who had negative axillary nodes after neoadjuvant...

leukemia
lymphoma

Noncovalent BTK Inhibitor in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In a phase III trial (BRUIN CLL-321) reported in the Journal of Clinical Oncology, Sharman et al compared treatment outcomes with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib vs investigator choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in patients ...

skin cancer

Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation

In a phase II trial (EBIN) reported in The Lancet Oncology, Robert et al investigated the survival benefit of adding induction encorafenib/binimetinib to nivolumab/ipilimumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutation. Study Details In the open-label trial, 271...

skin cancer

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to avelumab in patients with advanced cutaneous squamous cell carcinoma. Study Details In the U.S. multicenter trial, 57 evaluable patients were...

prostate cancer

Patient-Reported Outcomes and Symptomatic Skeletal Events With Lu-PSMA in Progressive Metastatic Castration-Resistant Prostate Cancer

In analyses from the phase III PSMAfore trial reported in The Lancet Oncology, Fizazi et al examined whether [177Lu]Lu–PSMA-617 (vipivotide tetraxetan; Lu-PSMA) improved patient-reported outcomes and delayed the time to first symptomatic skeletal events vs change of androgen receptor pathway (ARP)...

lung cancer

Neoadjuvant PD-1/PD-L1 Inhibition Plus Chemotherapy in Borderline-Resectable or Unresectable Stage III NSCLC

In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al examined whether neoadjuvant PD-1/PD-L1 inhibition plus platinum-based chemotherapy showed activity in patients with borderline-resectable/unresectable stage III non–small cell lung cancer (NSCLC). Study Details The study...

head and neck cancer

Concurrent vs Sequential Pembrolizumab With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Zandberg et al compared sequential vs concurrent pembrolizumab with chemoradiotherapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma. Study Details In the U.S. multicenter noncomparative trial, 80...

gastrointestinal cancer

Ramucirumab Beyond Progression Plus Irinotecan in Ramucirumab-Refractory Advanced Gastric Cancer

In a Japanese phase III trial (RINDBeRG) reported in the Journal of Clinical Oncology, Sakai et al assessed whether the addition of ramucirumab to irinotecan would improve overall survival in third- or later-line treatment of patients with advanced or recurrent gastric or gastroesophageal cancer...

colorectal cancer

Reduced-Dose Chemoradiotherapy in Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al compared short-term response rates with standard- vs reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the multicenter, open-label, noncomparative trial,...

gynecologic cancers

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...

pancreatic cancer

Cell-Free DNA Fragmentomics–Based Model for Early Detection of Pancreatic Cancer

In a Chinese study reported in the Journal of Clinical Oncology, Yin et al attempted to develop a cell-free DNA (cfDNA) fragmentomics–based model for early detection of pancreatic ductal adenocarcinoma.   Study Details The study consisted of training and validation cohorts from several Chinese...

lung cancer

Resectable NSCLC: Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy

In an analysis from the phase III CheckMate 816 trial reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Forde et al examined overall survival outcomes with the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with stage IB to IIIA...

breast cancer
supportive care

Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer

In a phase III trial (OASIS-4) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Cardoso et al attempted to determine whether the neurokinin-targeted therapy elinzanetant reduced the risk of vasomotor symptoms from endocrine therapy for patients with hormone...

multiple myeloma

MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma

In a French-Belgian phase III trial (MIDAS) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Perrot et al examined the outcomes of treatments guided by measurable residual disease (MRD) status in patients with newly diagnosed multiple myeloma.  Study Details In...

skin cancer

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma

In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...

colorectal cancer

CRISPR-Cas9–Edited Tumor-Infiltrating Lymphocytes in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology,1 Lou et al found that autologous tumor-infiltrating lymphocytes genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in patients...

prostate cancer

Localized Prostate Cancer: Long-Term Follow-up of Hypofractionated, Dose-Escalated vs Conventionally Fractionated RT

In a long-term follow-up of the phase III MD Anderson dose-escalated, hypofractionated prostate radiation study reported in the Journal of Clinical Oncology, Hassanzadeh et al compared hypofractionated intensity-modulated radiation therapy (HIMRT) vs conventionally fractionated intensity-modulated...

breast cancer
genomics/genetics

Prophylactic Radiation Therapy of the Contralateral Breast in BRCA Carriers with Early-Stage Breast Cancer

In a long-term follow-up of an Israeli phase II trial reported in a research letter in JAMA Oncology, Evron et al compared prophylactic radiation therapy (RT) of the contralateral breast vs surveillance in BRCA pathogenic variant carriers with early-stage breast cancer.   Study Details In the...

lung cancer

Navigational Bronchoscopy vs Transthoracic Needle Biopsy for Lung Nodules: Diagnostic Accuracy

In a study (VERITAS) reported in The New England Journal of Medicine, Lentz et al evaluated whether the diagnostic accuracy of navigational bronchoscopy was noninferior to that of transthoracic needle biopsy for malignancy or specific benign conditions in patients with peripheral pulmonary nodules. ...

gastroesophageal cancer

First-Line Nivolumab Plus Low-Dose Ipilimumab in MSI-H Advanced Gastric/GEJ Cancer

In a Japanese phase II study (NO LIMIT, WJOG13320G) reported in the Journal of Clinical Oncology, Kawakami et al evaluated whether first-line nivolumab plus low-dose ipilimumab showed activity in patients with microsatellite instability–high (MSI-H) advanced gastric/esophagogastric junction ...

issues in oncology
prostate cancer

Addition of Radium-223 to Stereotactic Ablative Radiotherapy in Oligometastatic Prostate Cancer

In a phase II trial (RAVENS) reported in the Journal of Clinical Oncology, Wang et al attempted to determine whether the addition of the bone metastasis–targeting agent radium-223 to stereotactic ablative radiotherapy improved progression-free survival as metastasis-directed therapy in patients...

issues in oncology
pancreatic cancer

FOLFIRINOX vs Gemcitabine in Nonresectable Locally Advanced Pancreatic Carcinoma

In a French phase III trial (NEOPAN) reported in the Journal of Clinical Oncology, Ducreux et al evaluated whether FOLFIRINOX (fluorouracil, oxaliplatin, and irinotecan) significantly improved progression-free survival vs gemcitabine in patients with locally advanced pancreatic carcinoma not...

lung cancer
immunotherapy

Harm-Benefit Balance of Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer

In a study reported in JAMA Oncology, Heyward et al examined the harm-benefit balance of immune checkpoint inhibitor use across lines of treatment in non–small cell lung cancer (NSCLC). Study Details The retrospective cohort study, conducted in 2024, involved 2013 to 2019 Surveillance,...

First-Line Nivolumab/Ipilimumab vs Lenvatinib or Sorafenib in Unresectable Hepatocellular Carcinoma

In a phase III trial (CheckMate 9DW) reported in The Lancet, Yau et al evaluated whether first-line nivolumab plus ipilimumab improved overall survival vs investigator's choice of lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. Study Details In the open-label trial,...

lymphoma

Enhanced CAR T-Cell Therapy for Lymphoma After Previous Failure on CAR T-Cell Therapy

In a single-center phase I trial reported in The New England Journal of Medicine, Svoboda et al assessed the safety, feasibility, and preliminary efficacy of an enhanced chimeric antigen receptor (CAR) T-cell therapy (huCART19-IL18) in patients with relapsed or refractory lymphoma after previous...

issues in oncology
solid tumors

Dose-Escalated Stereotactic Body Radiotherapy vs Conventional Radiotherapy for Painful Bone Metastases

In a Belgian phase III trial (ROBOMET) reported in the Journal of Clinical Oncology, Mercier et al attempted to determine whether dose-escalated, single-fraction stereotactic body radiotherapy was associated with statistically significant benefit vs conventional, single-fraction, 3D conformal...

issues in oncology
breast cancer

Mortality Associated With Risk-Adapted Adjuvant Therapy in Postmenopausal Women With Early Breast Cancer

In a Danish Breast Cancer Group nationwide prospective cohort study reported in The Lancet Oncology, Jensen et al attempted to develop a prognostic standard mortality rate index to predict excess mortality based on risk-adapted adjuvant therapy in postmenopausal patients with early-stage breast...

issues in oncology
pancreatic cancer

Addition of Tocilizumab to Nab-Paclitaxel and Gemcitabine in First-Line Treatment of Advanced Pancreatic Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Chen et al attempted to determine whether there is a benefit to adding tocilizumab to nab-paclitaxel and gemcitabine in the first-line treatment of patients with advanced pancreatic cancer. Study Details In the open-label trial, 141...

issues in oncology
breast cancer

Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers With Breast Cancer

In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved survival among women aged 40 or younger who have invasive breast cancer with germline BRCA1/2...

myelodysplastic syndromes

p53 Dysfunction in Myelodysplastic Syndromes

In a study reported in the Journal of Clinical Oncology, Zampini et al identified a proportion of patients with myelodysplastic syndromes who had nonmutational TP53 but p53 dysfunction, which was associated with poor disease outcomes.  Study Details The study involved data from a cohort of 6,204...

hepatobiliary cancer

Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma

In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...

issues in oncology
breast cancer

Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer

In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer. As stated by the investigators:...

issues in oncology

Antimicrobial Resistance in Outpatients With Cancer

In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...

issues in oncology
colorectal cancer

Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer

In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the ...

breast cancer

Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...

gastroesophageal cancer
gastrointestinal cancer

First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...

lung cancer

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al found that afatinib prolonged progression-free survival vs platinum-based chemotherapy in patients who had treatment-naive nonsquamous non–small cell lung cancer (NSCLC) with...

Overall Survival Analysis in CodeBreaK 300: Sotorasib Plus Panitumumab vs Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer

As reported in the Journal of Clinical Oncology by Pietrantonio et al, overall survival analysis in the phase III CodeBreaK 300 trial showed numeric improvement with sotorasib/panitumumab vs investigator's choice of treatment in patients with chemorefractory KRAS G12C-mutant metastatic colorectal...

CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer

In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in...

Advertisement

Advertisement




Advertisement